Kargbo RB
Independent Research Consultant, Middleton, Wisconsin 53562, United States.
ArticleDMT
Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms.
ArticlePsilocybin
Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics.
ArticlePsychedelics
From Solid-State Control to Predictive Precision: Building a Deployable Ecosystem for Psychedelic Therapeutics.
ArticlePsilocybin
Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations.
ArticleDMT
Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric Therapeutics.
ArticlePsilocybin
Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.
ArticlePsilocybin
Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy.
ArticlePsilocybin
Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations.
ArticlePsilocybin
Therapeutic Divergence in 5‑HT<sub>2</sub>A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome.
ArticlePsilocybin
Synthesis of Psilocin, Psilocybin and 5-MeO-DMT Succinate, All Labelled With Carbon-14 at the Indole 2-Position.
ArticlePsychedelics
Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.
ArticleDMT
Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.
ArticleDMT
Reducing Cardiovascular Side Effects of DMT Using Beta-Blockers.
ArticlePsilocybin
Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies.
ArticlePsychedelics
Unveiling Reality: Psychedelics, Neural Filtering, and the Future of Psychiatric Medicine.
ArticlePsychedelics
Innovative Approaches in Psychedelics, AI, and Communication: A Multi-Domain Perspective.
ArticlePsilocybin
Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.
ArticlePsychedelics
Integrating Artificial Intelligence and Digital Innovations in Psychedelic and Brain Therapeutics.
ArticlePsychedelics
Advances in Psychoactive Alkaloid Delivery, Ergoline Analogues, and Serotonin Receptor Modulation for Enhanced Therapeutic Outcomes.
ArticlePsychedelics
Harnessing Artificial Intelligence to Overcome Key Challenges in Psychedelic Research and Therapy.
ArticlePsilocybin
Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications.
ArticlePsilocybin
Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.
ArticleDMT
Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment.
ArticlePsilocybin
Expanding the Therapeutic Horizons of Psilocybin in Mental Health.
ArticlePsilocybin
Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine.
ArticlePsilocybin
Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience.
ArticlePsychedelics
The New Frontier in Neurotherapeutics: From Brain Stimulation to Novel Psychotropics.
ArticlePsilocybin
Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology.
ArticlePsilocybin
Pioneering Methods in Brain Optimization and Mental Health Treatment.
ArticleKetamine
Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders.
ArticlePsilocybin
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential.
ArticlePsychedelics
Exploring Next-Generation Therapeutics: Morphic Mixtures and Specified Salts for the Treatment of Mental Disorders and CNS Modulation.
ArticlePsychedelics
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI.
ArticleKetamine
Psychoplastogens: A Novel Therapeutic Approach for Neurological Diseases and Disorders.
ArticlePsychedelics
Microbiome: The Next Frontier in Psychedelic Renaissance.
ArticlePsychedelics
Unraveling Psychedelic Responses: Targeted Protein Degradation and Genetic Diversity.
ArticlePsilocybin
Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders.
ArticleMDMA
Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders.
ArticlePsychedelics
Psychedelic-Assisted Neuroplasticity for the Treatment of Mental Health Disorders.
ArticleLSD
Potential Treatment for Obsessive-Compulsive Disorder.
ArticleDMT
Application of Deuterated <i>N</i>,<i>N</i>-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders.
ArticleIbogaine
Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders.
ArticlePsilocybin
Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD).
ArticlePsychedelics
The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting.
ArticleDMT
5-MeO-DMT: Potential Use of Psychedelic-Induced Experiences in the Treatment of Psychological Disorders.
ArticlePsychedelics
Psychedelic Therapeutic: Potential Treatment for Headache Disorders.
ArticlePsilocybin
Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.
ArticlePsilocybin
Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity.
ArticlePsilocybin
Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin.
ArticlePsilocybin
Psilocybin Therapeutic Research: The Present and Future Paradigm.
ArticlePsilocybin